Biomarkers of parathyroid carcinoma

Endocrine Pathology

Volumn 23, Issue 4, 2012, Pages 221-231

  Erovic, Boban M ^a   Harris, Luke ^a   Jamali, Mina ^b   Goldstein, David P ^a   Irish, Jonathan C ^a   Asa, Sylvia L ^b   Mete, Ozgur ^b  

^a Wharton Head and Neck Center   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Angioinvasion; Bcl 2a; Parafibromin; Parathyroid carcinoma; Sonic hedgehog; Targeted anticancer therapy

Indexed keywords

BETA CATENIN; BMI1 PROTEIN; CD9 ANTIGEN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; GLUTATHIONE TRANSFERASE; INTERSTITIAL COLLAGENASE; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN BCL XL; PROTEIN CDC2P34; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SONIC HEDGEHOG PROTEIN; STRATIFIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; WNT PROTEIN;

ADULT; AGED; AKT SIGNALING PATHWAY; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; DATA ANALYSIS SOFTWARE; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL DEVICE; NECK DISSECTION; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROIDECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHH SIGNALING PATHWAY; SIGNAL TRANSDUCTION; THYMECTOMY; TUMOR VOLUME; WNT SIGNALING PATHWAY;

EID: 85027934957     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-012-9222-y     Document Type: Article

References (37)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985 and 1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 86:538-544. (Pubitemid 29347419)
2. Erovic BM, Goldstein DP, Kim D, Mete O, Brierly J, Tsang R, Freeman JL, Asa SL, Rotstein L, Irish JC (2012). Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck 2012, doi:10.1002/hed.22908.
3. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM (2007) Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109:1736-1741. (Pubitemid 46668534)
4. Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO (1992) Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16:724-731.
5. Chow E, Tsang RW, Brierley JD, Filice S (1998) Parathyroid carcinoma - the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 41:569-572. (Pubitemid 28275085)
6. Munson ND, Foote RL, Northcutt RC, Tiegs RD, Fitzpatrick LA, Grant CS, van Heerden JA, Thompson GB, Lloyd RV (2003) Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98:2378-2384. (Pubitemid 37466652)
7. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A. (2004) Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413-3420. (Pubitemid 38951913)
8. Schott M, Feldkamp J, Schattenberg D, Krueger T, Dotzenrath C, Seissler J, Scherbaum WA (2000) Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300-306. (Pubitemid 30176941)
9. Schott M, Feldkamp J, Schattenberg D, Seissler J, Scherbaum WA (1999) Dendritic cell immuno-therapy in disseminated parathyroid carcinoma. Lancet 353:1188-1189. (Pubitemid 29155234)
10. Mete O, Asa SL (2011) Pathological definition and clinical significance of vascular invasion in thyroid carcinomas derived from follicular epithelium. Modern Pathology 24:1545-1552.
11. Machiels JP, Schmitz S (2011) Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy. Curr Opin Oncol 23:241-248.
12. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama a A (2011) Treatment Of Non-small-cell Lung Cancer With Erlotinib Or Gefitinib. N Engl J Med 364:947-955
13. Chee CE, Sinicrope FA (2010) Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 39:601-613.
14. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23:289-304.
15. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896. (Pubitemid 350002890)
16. Bukowski RM (2010) Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 10:635-645.
17. Perrone MG, Scilimati A, Simone L, Vitale P (2010) Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 17:3769-805.
18. Kao J, Sikora AT, Fu S (2009). Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets 9:931-937.
19. Moreira L, Castells A (2010). Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 12:1888-1894.
20. Peukert S, Miller-Moslin K (2010) Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. Chem Med Chem 5:500-512.
21. Narita S, So A, Ettinger S, Hayashi N, Muramaki M, Fazli L, Kim Y, GleaveME (2008) GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgenindependent prostate cancer. Clin Cancer Res 14:5769-5777.
22. Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, Vose JM, Joshi SS (2008) Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma. Mol Cancer Ther 7:1450-1460.
23. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis (2008) Oncogene 27:2312-2319. (Pubitemid 351501782)
24. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer (2007) Toxicol Appl Pharmacol 224:360-368. (Pubitemid 47575672)
25. Erovic BM, Pammer J, Hollemann D, Woegerbauer M, Geleff S, Fischer MB, Burian M, Frommlet F, Neuchrist C (2003) Motilityrelated protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 25:848-857. (Pubitemid 37139897)
26. Kohmo S, Kijima T, Otani Y, Mori M, Minami T, Takahashi R, Nagatomo I, Takeda Y, Kida H, Goya S, Yoshida M, Kumagai T, Tachibana I, Yokota S, Kawase I (2010) Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res 70:8025-8035.
27. Takino T, Saeki H, Miyamori H, Kudo T, Sato H (2007) Inhibition of membrane-type 1 matrix metalloproteinase at cell-matrix adhesions. Cancer Res 67:11621-11629.
28. Thévenin AF, Zony CL, Bahnson BJ, Colman RF (2011) GST pi modulates JNK activity through a direct interaction with JNK substrate, ATF2. Protein Sci 20:834-848.
29. Edelman MJ (2006) Novel cytotoxic agents for non-small cell lung cancer. J Thorac Oncol 1:752-755. (Pubitemid 47163974)
30. Singh S, Okamura T, Ali-Osman F (2010) Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol 80:1343-1355.
31. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722-1729. (Pubitemid 37315009)
32. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A (1994) p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 78:1320-1324.
33. Cryns VL, Thor A, Xu HJ, Hu SX, Wierman ME, Vickery AL Jr, Benedict WF, Arnold A (1994) Loss of the retinoblastoma tumorsuppressor gene in parathyroid carcinoma. N Engl J Med 330:757 761. (Pubitemid 24080222)
34. Gill AJ, Clarkson A, Gimm O, et al. (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30:1140-1149. (Pubitemid 44299347)
35. Krebs LJ, Shattuck TM, Arnold A (2005) HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90:5015-5017. (Pubitemid 41262247)
36. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV (1999). Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 23:288-295. (Pubitemid 29117564)
37. DeLellis RA, Lloyd RV, Heitz PU, editors (2004) World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon.